Novartis’ Kisqali gains breakthrough status in premenopausal breast cancer
January 3, 2018Research and Development, Sales and Marketing Kisqali, Novartis, biotech, drugs, pharma, pharmaceutical
Novartis has received a major boost in its efforts to broaden use of its CDK4/6 inhibitor, by receiving a breakthrough …
Mallinckrodt bolsters business with $1.2bn buyout
January 3, 2018Research and Development, Sales and Marketing Mallinckrodt, drugs, pharma, pharmaceutical, sucampo
Mallinckrodt has endured a tough 2017, with its share price falling by half over the course of the year. This …
Winter crisis hits, NHS hospitals cancel non-emergency operations
January 3, 2018Medical Communications, Research and Development NHS, biotech, drugs, pharma, pharmaceutical
There was ample warning that the NHS looked set to face another difficult winter season, the predictions now look to …
Diabetes drugs show potential in treating Alzheimer’s
January 3, 2018Research and Development Alzheimer's disease, biotech, drugs, pharma, pharmaceutical
A group of researchers at Lancaster University have identified a drug currently used to treat type 2 diabetes that has …
GW Pharma applies to both EU and US for lead product
January 2, 2018Manufacturing and Production, Sales and Marketing GW Pharma, biotech, drugs, pharma, pharmaceutical
GW Pharmaceuticals had a busy festive period, after it announced that it had submitted to both the EU and the …
NICE to take another look at Pfizer’s leukaemia drug
January 2, 2018Manufacturing and Production, Sales and Marketing NICE, Pfizer, biotech, drugs, pharma, pharmaceutical
Back in August of 2017, NICE rejected Pfizer’s Besponsa on cost-effectiveness grounds and the pharma giant was not best pleased. …
FDA approves shock wave wound healing device
January 2, 2018Manufacturing and Production, Sales and Marketing FDA, biotech, drugs, pharma, pharmaceutical
Continuing its recent trend to promote innovative new technologies, the FDA has announced that it has approved a medical device …
Mylan and Biocon biosimilar approval expands to Brazil
January 2, 2018Manufacturing and Production, Sales and Marketing Biocon, Herceptin, Mylan, biosimilar, biotech, drugs, pharma, pharmaceutical
Since Mylan and Biocon managed to gain US FDA approval for its Herceptin (Trastuzumab) biosimilar, it has forged ahead in …
Valeant and Pershing take $290m hit over insider trading
January 2, 2018Manufacturing and Production, Sales and Marketing Bill Ackman, Pershing Square, Valeant, biotech, drugs, pharma, pharmaceutical
Valeant Pharmaceuticals will be hoping it can begin 2018 as a fresh start, after a turbulent few years, to say …
Pharmafile.com’s top ten stories of 2017
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit
After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …
Seven pharma trends for 2018
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing
Pharmafile.com looks ahead to signpost what we expect will be the key industry trends through the course of 2018.The value of …
La Jolla Pharmaceutical scores FDA approval for blood pressure treatment
December 22, 2017Medical Communications, Sales and Marketing FDA, La Jolla pharmaceutical, blood pressure, pharma
The FDA has announced that it has approved La Jolla Pharmaceutical’s Giapreza (angiotensin II) injection for intravenous infusion to increase …
Novartis hit by court loss, could spur numerous cases across industry
December 22, 2017Medical Communications, Sales and Marketing Novartis, biotech, drugs, pharma, pharmaceutical
In a landmark ruling, a Californian court has found that a brand name manufacturer of a drug could be held …
Roche boosts oncology portfolio with $1.7bn acquisition
December 22, 2017Medical Communications, Sales and Marketing Roche, biotech, drugs, ignyta, pharma, pharmaceutical
Roche has announced that it will buy Ignyta, a San Diego-based biotech that has a pipeline of oncology drugs, for …
Eisai and Biogen Alzheimer’s drug stumbles at P2
December 21, 2017Medical Communications, Research and Development Biogen, Eisai, biotech, drugs, pharma, pharmaceutical
Only a few months ago, it was announced that Eisai had decided to opt into the development process of BAN2401. …
Higher mutational burdens in tumours linked to greater immunotherapy success, study finds
December 21, 2017Research and Development Cancer, Johns Hopkins Kimmel Cancer Center, checkpoint inhibitors, mutational burden, pharma
New research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Cancer Institute for Cancer Immunotherapy has indicated that …
FDA grants breast cancer approval to Roche’s Perjeta/Herceptin combo therapy
December 21, 2017Sales and Marketing Cancer, FDA, Herceptin, Perjeta, Roche, breast cancer, pharma
Roche has announced that the FDA has granted approval to Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and a (Perjeta-based) …
The rare disease climate in Europe
December 21, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, rare disease
Continuing on from this week’s earlier feature on the rare disease situation in the US, Pharmafile moves its attention onto …
Pfizer’s Bosulif scores US green light in leukaemia sub-type
December 21, 2017Sales and Marketing FDA, Pfizer, bosulif, leukaemia, leukemia, pharma
Pfizer has revealed that its tyrosine kinase inhibitor Bosulif (bosutinib) has been awarded marketing authorisation from the FDA in the …
MSD and Pfizer receive approval for combo diabetes therapy
December 21, 2017Sales and Marketing MSD, Pfizer, biotech, diabetes, drugs, pharma, pharmaceutical
MSD (known as Merck in North America) and Pfizer have announced that their sodium-glucose co-transporter 2 (SGLT2) inhibitor has received …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
